SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : King Pharmaceuticals, Inc. (Nasdaq:KG)(Was KING) -- Ignore unavailable to you. Want to Upgrade?

To: radman33 who wrote (43)3/7/2001 11:54:47 PM
From: gregor1 Recommendation  Respond to of 61
 
Jay: I'm sorry I do not follow this one now..Gregor



To: radman33 who wrote (43)3/8/2001 12:20:26 AM
From: Sr K  Respond to of 61
 
I still follow it, but sold it by allowing a 40 call to take it away. My 4th time in JMED.

It still seems overpriced to me, with 2002 company projections of $1.48. This is a stock I only enter for 25% in a year, so I would not consider it over $30.

25 x 1.48 seems fair next year = $37, divide by 1.25 = 29.60.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News